Palabras clave
Epidemiología
Organismos multirresistentes
Infecciones de Transmisión Sexual
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Descubrir evidencias científicas acerca de las tendencias y repercusiones clínicas inerentes en la corrección de resistencia a los medicamentos para el tratamiento de infecciones de transmisión sexual. Métodos: Foi utilizado para seleccionar dos estudios o modelo PRISMA con la inclusión de pesquisas publicadas no período de 2018 a 2023 y excluidos aquellos que no respondan a la pergunta norteadora del estudio. Resultados: Como principales IST asociados al foro problemático de gonorrea, citados en 56% de los artículos, seguidos por uretrita y cervicitis en 44%, y clamídia en 8%. Las principales clases de medicamentos asociados a resistencia bacteriana en IST son macrolídeos (40%), cefalosporinas (20%) y fluoroquinolonas (16%). Algunas de las principales tendencias detectadas han aumentado la propagación de la resistencia, principalmente para Neisseria gonorrhoeae. Consideraciones finales: Los datos evidencian la amenaza global de patógenos causadores de IST resistentes a los antimicrobianos, proyectadas para causar un aumento significativo en las taxas de morbilidad, mortalidad y, así, se faz primordiales intervenciones innovadoras para preservar la eficacia de los tratamientos y atender a las metas globales. de salud pública. Además, el tratamiento con base en evidencias microbiológicas y racionales, como una implementación de programas eficaces para rastreo y vigilancia local y global, es crucial.
Referencias
BACHMANN LH, et al. Prevalence of Mycoplasma genitalium infection, antimicrobial resistance mutations, and symptom resolution following treatment of urethritis. Clin Infect Dis [Internet]. 2020; 71(10): 624–32.
BEALE MA, et al. Genomic epidemiology of syphilis reveals independent emergence of macrolide resistance across multiple circulating lineages. Nat Commun [Internet]. 2019; 10(1): 3255.
BERÇOT B, et al. High prevalence and high rate of antibiotic resistance of Mycoplasma genitalium infections in men who have sex with men: A substudy of the ANRS IPERGAY pre-exposure prophylaxis trial. Clin Infect Dis [Internet]. 2021; 73(7): 2127–33.
DE ASSIS LV, et al. Chlamydia Trachomatis e o risco de doença inflamatória pélvica evoluindo para quadro de infertilidade feminina: uma revisão bibliográfica. Acervo Científico [Internet]. 2021; 19: 5669.
FIFER H, et al. Frequency and correlates of Mycoplasma genitalium antimicrobial resistance mutations and their association with treatment outcomes: Findings from a national sentinel surveillance pilot in England. Sex Transm Dis [Internet]. 2021; 48(12): 951–4.
FLETCHER-LARTEY S, et al. Trends in antimicrobial resistance patterns in Neisseria gonorrhoeae in Australia and New Zealand: A meta-analysis and systematic review. Antibiotics (Basel) [Internet]. 2019; 8(4): 191.
FRACAROLLI IFL, et al. Colonização bacteriana e resistência antimicrobiana em trabalhadores de saúde: revisão integrativa. Acta Paul Enferm [Internet]. 2017; 30(6): 651–7.
GUO C, et al. Transmitted drug resistance in antiretroviral therapy-naive persons with acute/early/primary HIV infection: A systematic review and meta-analysis. Front Pharmacol [Internet]. 2021; 12.
IWUJI C, et al. A systematic review of antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium in sub-Saharan Africa. J Antimicrob Chemother [Internet]. 2022; 77(8): 2074–93.
KHOSROPOUR CM, et al. High prevalence of vaginal and rectal Mycoplasma genitalium macrolide resistance among female sexually transmitted disease clinic patients in Seattle, Washington. Sex Transm Dis [Internet]. 2020; 47(5): 321–5.
LAI C-C, et al. Increased antimicrobial resistance during the COVID-19 pandemic. Int J Antimicrob Agents [Internet]. 2021; 57(4): 106324.
LEE H, et al. Emergence and spread of cephalosporin-resistantNeisseria gonorrhoeaewith mosaicpenAalleles, South Korea, 2012–2017. Emerg Infect Dis [Internet]. 2019; 25(3): 416–24.
LIN EY, et al. Epidemiology, treatments, and vaccine development for antimicrobial-resistant Neisseria gonorrhoeae: Current strategies and future directions. Drugs [Internet]. 2021; 81(10): 1153–69.
LU Z, et al. Global status of Azithromycin and Erythromycin Resistance Rates in Neisseria gonorrhoeae: A Systematic Review and Meta-analysis. Yale J Biol Med. 2022; 95(4): 465–78.
MABONGA E, et al. Complete ciprofloxacin resistance in gonococcal isolates in an urban Ugandan clinic: findings from a cross-sectional study. Int J STD AIDS [Internet]. 2019; 30(3): 256–63.
MARTENS L, et al. Macrolide-Resistant Mycoplasma genitalium in Southeastern Region of the Netherlands, 2014–2017. Emerg Infect Dis [Internet]. 2019; 25(7): 1297–303.
MELENDEZ JH, et al. Retrospective analysis of Ugandan men with urethritis reveals Mycoplasma genitalium and associated macrolide resistance. Microbiol Spectr [Internet]. 2022; 10(2).
MELNYK BM e FINEOUT-OVERHOLT E. Evidence-based practice in nursing and healthcare: A guide to best practice. Philadelphia, PA: Wolters Kluwer Health. 10–16
MITCHELL HD, et al. Prevalence and risk factors of bacterial enteric pathogens in men who have sex with men: A cross-sectional study at the UK’s largest sexual health service. J Infect [Internet]. 2023; 86(1): 33–40.
MOJICA MF, et al. The urgent need for metallo-β-lactamase inhibitors: an unattended global threat. Lancet Infect Dis [Internet]. 2022; 22(1): 28–34.
MONDEJA BA, et al. Macrolide-resistant Mycoplasma genitalium infections in Cuban patients: an underestimated health problem. BMC Infect Dis [Internet]. 2018; 18(1).
NAKKU-JOLOBA E, et al. Prevalence and antimicrobial resistance profiles of Neisseria gonorrhea and Chlamydia trachomatis isolated from individuals attending STD clinics in Kampala, Uganda. Afr Health Sci [Internet]. 2022; 22(3): 62–71.
PASCOAL IL, et al. Trichomonas vaginalis como Co-Fator na propagação do HIV em mulheres: uma revisão de literatura Braz. J. Develop. [Internet]. 2021; 7(5): 52660-73.
PINTO VM, et al. Fatores associados às infecções sexualmente transmissíveis: inquérito populacional no município de São Paulo, Brasil. Cien Saude Colet [Internet]. 2018; 23(7): 2423–32.
PITT R, et al. Antimicrobial resistance in Mycoplasma genitalium sampled from the British general population. Sex Transm Infect [Internet]. 2020; 96(6): 464–8.
POLLY M, et al. Impact of the COVID-19 pandemic on the incidence of multidrug-resistant bacterial infections in an acute care hospital in Brazil. Am J Infect Control [Internet]. 2022; 50(1): 32–8.
SALMERÓN P, et al. Neisseria gonorrhoeae antimicrobial resistance in Spain: a prospective multicentre study. J Antimicrob Chemother [Internet]. 2021; 76(6): 1523–31.
SANDOVAL MM, et al. Antimicrobial resistance of Neisseria gonorrhoeae in Latin American countries: a systematic review. J Antimicrob Chemother [Internet]. 2023; 78(6): 1322–36.
SCHAEFFER J, et al. Rifampicin resistance associated with rpoB mutations in Neisseria gonorrhoeae clinical strains isolated in Austria, 2016 to 2020. Microbiol Spectr [Internet]. 2022; 10(3).
SHANNON CL e KLAUSNER JD. The growing epidemic of sexually transmitted infections in adolescents: a neglected population. Curr Opin Pediatr [Internet]. 2018; 30(1): 137–43.
SILVA EFO, et al. Fatores associados ao aumento de infecções sexualmente transmissíveis no público idoso. Revista Eletrônica Acervo Saúde, 2023; 23(3): 11813.
SIMÕES LA, et al. Fatores associados à coinfecção HIV/sífilis no início da terapia antirretroviral. Rev Saúde Publica. 2022; 56: 59.
SUTHERLAND SBN. Debate Pack O’Neill. Review into Antibiotic Resistance. House of Commons; 2017; (1): 1–41.
SWEENEY EL, et al. Levels of Mycoplasma genitalium antimicrobial resistance differ by both region and gender in the state of Queensland, Australia: Implications for treatment guidelines. J Clin Microbiol [Internet]. 2019; 57(3).
TEIXEIRA LG, et al. O perfil epidemiológico da AIDS no Brasil. Braz J Hea Rev [Internet]. 2022; 5(1): 1980–92.
TIEN V, et al. Antimicrobial resistance in sexually transmitted infections. J Travel Med [Internet]. 2020; 27(1).
UNEMO M, et al. Clinical and analytical evaluation of the new Aptima Mycoplasma genitalium assay, with data on M. genitalium prevalence and antimicrobial resistance in M. genitalium in Denmark, Norway and Sweden in 2016. Clin Microbiol Infect [Internet]. 2018; 24(5): 533–9.
UNEMO M, et al. Sexually transmitted infections: challenges ahead. Lancet Infect Dis [Internet]. 2017; 17(8): 235–79.
VICENTE CMM, et al. International travels and transmission of multidrug resistant Neisseria gonorrhoeae in Europe: A systematic review. Travel Med Infect Dis [Internet]. 2022; 49(102401): 102401.
VISSER M, et al. Trends and regional variations of gonococcal antimicrobial resistance in the Netherlands, 2013 to 2019. Euro Surveill [Internet]. 2022; 27(34).
WILLIE B, et al. The prevalence of antimicrobial resistant Neisseria gonorrhoeae in Papua New Guinea: A systematic review and meta-analysis. Int J Environ Res Public Health [Internet]. 2022; 19(3): 1520.
WORLD HEALTH ORGANIZATION. HIV drug resistance report, 2021.